ArticleJournal of clinical microbiology2012
Cation concentration variability of four distinct Mueller-Hinton agar brands influences polymyxin B susceptibility results.
Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Sphingosine synergizes with polymyxin antibiotics againstMicrobiology (Reading, England) · 2026Article
- The Public Health Risks of Colistin Resistance in Dogs and Cats: A One Health Perspective Review.Antibiotics (Basel, Switzerland) · 2025Review
- Navigating the complexities of drug development for metallo-β-lactamase inhibitors.RSC medicinal chemistry · 2025Review
- Comment on: Comparison of carbapenem MIC for NDM-producing Enterobacterales by different AST methods: considerations for media composition.JAC-antimicrobial resistance · 2024Article
- Ironing out Persisters? Revisiting the Iron Chelation Strategy to Target Planktonic Bacterial Persisters Harboured in Carbapenem-ResistantMicroorganisms · 2024Article
- Dissecting components of theMicrobiology spectrum · 2024Article
- Comparative genomics reveals the correlations of stress response genes and bacteriophages in developing antibiotic resistance ofmSystems · 2023Article
- Gallium Nitrate Enhances Antimicrobial Activity of Colistin against Klebsiella pneumoniae by Inducing Reactive Oxygen Species Accumulation.Microbiology spectrum · 2023Article
- Azithromycin: An Underappreciated Quinolone-Sparing Oral Treatment forAntibiotics (Basel, Switzerland) · 2022Article
- Biomarker enrichment medium: A defined medium for metabolomic analysis of microbial pathogens.Frontiers in microbiology · 2022Article
- Validation of Selective Agars for Detection and Quantification of Escherichia coli Strains Resistant to Critically Important Antimicrobials.Microbiology spectrum · 2021Article
- Machine Learning Establishes Single-Cell Calcium Dynamics as an Early Indicator of Antibiotic Response.Microorganisms · 2021Article
- Proteomic response of Escherichia coli to a membrane lytic and iron chelating truncated Amaranthus tricolor defensin.BMC microbiology · 2021Article
- Improved Detection ofFrontiers in microbiology · 2021Article
- Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo-β-Lactamase-ProducingJournal of clinical microbiology · 2020Article
- Genetic Determinants Enabling Medium-Dependent Adaptation to Nafcillin in Methicillin-Resistant Staphylococcus aureus.mSystems · 2020Article
- The Iron-chelator, N,N'-bis (2-hydroxybenzyl) Ethylenediamine-N,N'-Diacetic acid is an Effective Colistin Adjunct against Clinical Strains of Biofilm-DwellingAntibiotics (Basel, Switzerland) · 2020Article
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Review
- Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.Journal of clinical microbiology · 2019Review
- Development of New Tools to Detect Colistin-Resistance among Enterobacteriaceae Strains.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyxins have been the only alternative therapeutic option for the treatment of serious infections caused by multidrug-resistant Acinetobacter baumannii or Pseudomonas aeruginosa isolates. For this reason, it is of crucial importance that susceptibility tests provide accurate results when testing these drug-pathogen combinations. In this study, the effect of cation concentration variability found on different commercial brands of Mueller-Hinton agar (MHA) for testing polymyxin B susceptibility was evaluated. The polymyxin B susceptibilities determined using Etest and disk diffusion were compared to those determined by the CLSI reference broth microdilution method. In general, the polymyxin B MIC values were higher when determined by Etest than when determined by broth microdilution against both A. baumannii and P. aeruginosa isolates. A high very major error rate (10%) was observed, as well as a trend toward lower MICs, compared to those determined by broth microdilution when the Merck MHA was tested by Etest. Poor essential agreement rates (10 to 70%) were observed for P. aeruginosa when all MHA brands were tested by Etest. Although an excellent categorical agreement rate (100%) was seen between the disk diffusion and broth microdilution methods for P. aeruginosa, larger zones of inhibition were shown obtained using the Merck MHA. The high cation concentration variability found for the MHA brands tested correlated to the low accuracy, and discrepancies in the polymyxin B MICs were determined by Etest method, particularly for P. aeruginosa isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.